This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Katherine Tuttle
Katherine
Tuttle
University of Washington, Washington, US

Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health, Regional Principal Investigator of the Institute of Translational Health Sciences and Professor of Medicine at the University of Washington. She oversees a regional network of 17 clinical research centers and chairs the research Regional Executive Council for the University of Washington. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University in Chicago. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis. Her Nephrology fellowship training was performed at the University of Texas Health Science Center in San Antonio.

 

Dr. Tuttle’s major research interests are in diabetes and chronic kidney disease. As a clinical and translational scientist, she has published over 350 original peer-reviewed articles. Early in her career, her first independently awarded research grant produced a landmark study elucidating physiological principles underlying glomerular hyperfiltration in humans with diabetes. This foundational work led to a number of subsequent physiological and pre-clinical studies that laid a foundation for new therapeutic targets in clinical trials. She has seen that work to the finish line over more than three decades to help deliver SGLT2 inhibition as the most impactful therapy to-date to reduce risks of kidney failure, cardiovascular events, and death in persons with and without diabetes. Dr. Tuttle has also been a leading investigator across the translational arc for other breakthrough therapies, including incretins and anti-inflammatory agents. She led the original clinical trial that elevated glucagon-like peptide-1 receptor agonists to potential therapeutics for chronic kidney disease, which is being tested in ongoing trials. She leads the Center for Kidney Disease Research, Education and Hope (CURE-CKD) Registry of real-world data for chronic kidney disease, diabetes, prediabetes, and hypertension from nearly 4 million health system patients. In sum, her collective work has shaped the “pillars of therapy“ approach to chronic kidney disease in a most fundamental manner across the spectrum of scientific discovery, clinical trials, and population level implementation.

Dr. Tuttle is Chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology. She served on the inaugural Board of Directors for the Kidney Health Initiative and has chaired numerous working groups and committees for organizations including the National Institutes of Health, the American Society of Nephrology, the International Society of Nephrology, Kidney Disease Improving Global Outcomes, the National Kidney Foundation, and the American Diabetes Association. Dr. Tuttle has received many honors and awards including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology, the Medal of Excellence from the American Association of Kidney Patients, the Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two University of Washington Outstanding Clinical Faculty Awards.

properties.alt

Peter Rossing

Steno Diabetes Center Copenhagen, Copenhagen, Denmark


Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center Copenhagen research team dedicated to the research of micro-and macrovascular complications of diabetes.

 

Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.

 

He was coordinator of the EU FP7 project PRIORITY demonstrating that  urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy, the STENO1 and member of several trial steering groups and guideline committees.

 

He has co-authored >650 papers and his h-index is 86. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD and the E. Bierman award from ADA and the Hormon Medal from European Society of Endocrinology. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry


Read full bio
properties.alt

Per-Henrik Groop

University of Helsinki, Helsinki, Finland


Professor Per-Henrik Groop, MD, DMSc, FRCPE graduated from the University of Helsinki in 1982. Following post-doctoral studies at Guy’s Hospital, University of London, under Professor Giancarlo Viberti, Professor Groop returned to Helsinki as Consultant of Nephrology. He served as Professor of Nephrology (Chair) 2010-2015 and is currently Professor of Internal Medicine (Chair) at the University of Helsinki. He is also Chief Physician at the Department of Nephrology, University of Helsinki and Helsinki University Hospital and Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland. He is Adjunct Professor at the Department of Diabetes, Monash University, Melbourne, Australia.

 

His research is focused on the dissection of the pathogenesis of diabetic complications with special emphasis on diabetic nephropathy. In order to provide a unique set of clinical resources with high power to identify genes and genetic variants associated with diabetic complications, Professor Groop initiated the large, nationwide FinnDiane Study in 1997. To date, this landmark study comprises 9000 patients with Type 1 Diabetes and their family members recruited via a comprehensive network of 92 hospitals and healthcare centres throughout Finland. His FinnDiane Research Group represents an inter-disciplinary team of 58 scientists, post-graduate students and personnel.

 

Professor Groop served as Associate Editor of Diabetologia, 2005–2007, and as member of the Advisory Board, 2008–2011. He was Associate Editor of Kidney International and International Diabetes Monitor, 2007–2011. He is currently on the Editorial Board of Diabetes Care. He was Chairman of the EASD Scientist Training Course, 2007–2013, President of the European Diabetic Nephropathy Study Group (EDNSG), 2008–2010, and Honorary Secretary of the EASD 2013-2016. He is since 2011 the chairman of the Signe and Ane Gyllenberg Foundation. He was awarded the prestigious EASD Castelli Pedroli Prize – 24th Camillo Golgi Lecture in 2009, the Novo Nordisk Foundation Lecture in 2012, and the IDF Award for Clinical and Therapeutic Research 2019.

 

Professor Groop has published more than 470 peer-reviewed original articles in high-impact journals, 40 reviews and book chapters, more than 50 papers in his native languages Swedish and Finnish as well as 730 abstracts presented at major international meetings.


Read full bio
properties.alt

Johannes Mann

University of Erlangen-Nürnberg, Erlangen, Germany


Johannes F. E. Mann, M.D., is currently (since 1989) full Professor of Medicine at the University of Erlangen-Nürnberg and Head, KfH Kidney Center, Munich, both in Germany. He is also (since 2010) Senior International Scholar at Population Health Research Institute, McMaster University, Hamilton, Canada.

 

His previous assignments include Director of Dept. of Nephrology, Munich General Hospitals, staff member and assistant Professor of Medicine, Dept. of Medicine, University of Heidelberg, Germany, and research fellowships in Pharmacology at the Universities of Montreal, Canada and of Heidelberg, Germany.

 

Professor Mann, a board-certified specialist in Internal Medicine, in Nephrology, in Intensive Care and in Pharmacology, was an officer of the German Societies of Medicine and of Nephrology, of the International Society of Nephrology and is on the editorial board of major journals of nephrology.

 

His scientific work includes about 300 original paper. His H-Index was 88 in 2021; his citations rank among the top 25 of European nephrologists according to Lab Times. Some of his papers, published in Nature, NEJM, Lancet, JAMA and Ann Int Med, were cited more than 5000 times, total citations are over 45,000.

 

The work of Professor Mann concerned initially the physiology of the renin-angiotensin system in experimental animals and later the role of this system for diseases of the kidney, the heart, the arteries, and for diabetes and its damages. From there, his interest moved to the treatment and prevention of progressive renal diseases, including diabetic and hypertensive kidney disease.


Read full bio